Dermatopathic Lymphadenopathy Associated with Immune-related Adverse Event-induced Skin Disorder Following Ipilimumab and Nivolumab Therapy: a Case Report

Key Points

• The study aims to explore the association between dermatopathic lymphadenopathy and skin disorders caused by immune-related adverse events during cancer therapy.
• Presented a case of a 76-year-old male diagnosed with malignant pleural mesothelioma.
• Administered ipilimumab and nivolumab therapy.
• Monitored immune-related adverse events and lymph node changes through imaging and biopsy.
• Developed grade 1 immune-related skin disorder that progressed to grade 3.
• Lymphadenopathy was identified through CT imaging.
• Biopsy confirmed the diagnosis of dermatopathic lymphadenopathy linked to the immune-related skin disorder.